Avoro Capital Advisors Reduces $15M in Autolus Therapeutics plc ($AUTL)

Avoro Capital Advisors has completely sold out of its position in Autolus Therapeutics plc (NasdaqGS:AUTL). According to the latest 13F filing with the SEC, Avoro sold all 9,910,642 shares it previously held, resulting in a 100% reduction in its stake. This move leaves Avoro with no shares in the company as of the reporting period.

What Changed in Avoro Capital Advisors' Autolus Position

Avoro Capital Advisors significantly reduced its exposure to Autolus Therapeutics by selling all 9,910,642 shares it previously held. This marks a 100% decrease in its position, leaving Avoro with no remaining shares in the biotechnology firm.

Other Institutional Activity in Autolus

Other institutional investors have shown varied interest in Autolus Therapeutics. MAK Capital One LLC increased its holdings by 3,616,144 shares, bringing its total to 33,621,487 shares valued at approximately $46.4 million. Armistice Capital, LLC, on the other hand, reduced its stake by 1,700,000 shares, ending with 15,800,000 shares worth about $21.8 million. Meanwhile, Blackstone Inc. and Syncona Portfolio Ltd maintained their positions, with Blackstone holding 20,485,611 shares valued at $28.3 million and Syncona Portfolio holding 16,640,720 shares worth $22.96 million.

Autolus Therapeutics Stock Snapshot

Shares of Autolus Therapeutics (NasdaqGS:AUTL) are currently trading at $1.56. The company has a market cap of $415.2 million and does not have a meaningful P/E ratio as it is not currently profitable. The stock's 52-week range spans from $1.18 to $2.70, with a 50-day moving average of $1.57 and a 200-day moving average of $1.53. Autolus boasts strong liquidity, with a current ratio of 11.05 and a quick ratio of 10.32.

Recent Earnings

In its latest earnings report, Autolus Therapeutics posted revenue of $1.08 million. Despite this, the company is not yet profitable, reflected in a negative return on equity of -29.6%. Investors can look forward to the next earnings update on August 14, 2026.

Insider Buying and Selling at Autolus Therapeutics plc

Insider activity at Autolus includes planned sales by Martin Pule, who sold 698,741 shares at prices of $4.00 and $4.23 each on September 16, 2024. These transactions were executed as part of a pre-arranged trading plan.

Analysts Set New Price Targets

Analysts remain optimistic about Autolus Therapeutics' prospects. On May 14, 2026, HC Wainwright & Co. maintained its 'buy' rating with a price target of $10.00. Similarly, Needham reiterated its 'buy' rating with the same target on March 27, 2026. The consensus among analysts is a 'strong buy', with a mean target price of $8.71 based on nine opinions.

About Autolus Therapeutics

Autolus Therapeutics plc is a biotechnology company based in London, UK, specializing in the development of T cell therapies for cancer and autoimmune diseases. The company is known for its innovative gene therapy products, such as AUCATZYL, and is actively involved in clinical trials for various conditions, including systemic lupus erythematosus and multiple sclerosis. Founded in 2014, Autolus is led by CEO Dr. Christian Martin Itin and employs around 752 people.

Bottom Line

Avoro Capital Advisors' decision to exit its position in Autolus Therapeutics reflects a significant shift in its investment strategy. Despite this, other institutional investors continue to engage with the company, showing mixed actions. Investors keep a close eye on Autolus due to its innovative T cell therapies and ongoing clinical trials. As always, remember that 13F filings are backward-looking and may not represent the current positions of institutional investors.